To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

March 24, 2025

Study Completion Date

April 22, 2025

Conditions
Healthy
Interventions
DRUG

Treatment A_Period 1

"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment B_Period 2

"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment A_Period 3

"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment B_Period 4

"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment B_Period 1

"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment A_Period 2

"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment B_Period 3

"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"

DRUG

Treatment A_Period 4

"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"

Trial Locations (1)

14096

Metro Hospital, Anyang-si

Sponsors

Lead Sponsor

All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY

NCT06754943 - To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 | Biotech Hunter | Biotech Hunter